INVION LIMITED

INVESTOR PRESENTATION - INVION LIMITED

ASX:IVX

INVION LIMITED

Health Care

Invion Limited (IVX) is a clinical-stage drug development company in the biotechnology and pharmaceutical industry in Australia. IVX has three key development programs: INV102 for inflammatory respiratory disease; INV104, a leukotriene receptor antagonist; and, INV103, a modified, naturally occurring human protein. Former Names Cbio Limited (CBZ), 04/09/2012.

Market Cap

55.01m

Price at Close

$0.01

4w avg. Volume

1.16m

4w avg. Turnover

$10.57k

Announcements
announcementt+2 movementdate
  • Cleansing Notice and Appendix 2A

    Issued Capital

  • -

    12 Aug 2020

-

12 Aug 2020
  • Change of Company Addresses

    Company Administration

  • 0.00%

    07 Aug 2020

0.00%

07 Aug 2020
  • Business Update and Change to Board and Management

    Progress Report · Market sensitive

  • 0.00%

    28 Jul 2020

0.00%

28 Jul 2020
  • Activities Report and Appendix 4C June 2020 Quarter

    Commitments test entity quarterly reports · Market sensitive

  • 0.00%

    28 Jul 2020

0.00%

28 Jul 2020
  • Appointment of M Leydin as Chief Financial Officer

    Company Administration

  • 0.00%

    12 Jul 2020

0.00%

12 Jul 2020
  • Invion subsidiary signs Supply Agreement with Pavay Biotech

    Progress Report · Market sensitive

  • 0.00%

    30 Jun 2020

0.00%

30 Jun 2020
  • Acceptance of New Zealand Patent Application

    Progress Report

  • +14.29%

    22 Jun 2020

+14.29%

22 Jun 2020
  • Program Update - March 2020 quarter

    Periodic Reports

  • 0.00%

    20 Apr 2020

0.00%

20 Apr 2020
  • Appendix 4C - March 2020 quarter

    Commitments test entity quarterly reports · Market sensitive

  • 0.00%

    20 Apr 2020

0.00%

20 Apr 2020
  • Preliminary data links Photosoft with immune response

    Progress Report

  • +12.50%

    14 Apr 2020

+12.50%

14 Apr 2020
Market Data

Current Price

$0.01

52WK HIGH

$0.026

52WK LOW

$0.006

1YR RETURN

-37.50%

1YR RETURN VS. SECTOR

-59.63%

90 DAY RETURN

+25.00%

ASX RANK

953

/2,032

SECTOR RANK

13

/32

SHARES OUTSTANDING

5.50b
ASX:IVX

INVION LIMITED

Health Care

Invion Limited (IVX) is a clinical-stage drug development company in the biotechnology and pharmaceutical industry in Australia. IVX has three key development programs: INV102 for inflammatory respiratory disease; INV104, a leukotriene receptor antagonist; and, INV103, a modified, naturally occurring human protein. Former Names Cbio Limited (CBZ), 04/09/2012.

Market Cap

55.01m

Price at Close

$0.01

4w avg. Volume

1.16m

4w avg. Turnover

$10.57k

ASX:IVX is not raising right now

Want to invest?

Fresh Equities

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.

Support

Ask Fresh

Archive
Contact Us

Level 7, 388 Bourke St
Melbourne VIC 3000
Australia

(03) 9028 2888

deals@freshequities.com

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.